Repeatability of Cerebral Perfusion Using Dynamic Susceptibility Contrast MRI in Glioblastoma Patients1,2
Cited by (0)
- 1
This work was supported by NCI/NIH R21CA117079, R01CA129371, and K24CA125440 (T.B.); NIH S10RR023401, 5R01NS069696, and 5R01NS060918 (S.M.S.); Saic-Frederick Inc. grant 26XS263 (T.B.); Norwegian Research Council grant 191088/V50 and Norwegian Cancer Society Grant 3434180 (K.E.E.); Harvard Catalyst grant M01-RR-01066 (T.B.); and NIH Awards UL1 RR025758 (T.B. and B.R.) and R01NS059775 (O.W.); Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH Award UL1 TR001102) and financial contributions from Harvard University and its affiliated academic healthcare centers. This work also involved the use of instrumentation supported by the NCRR Shared Instrumentation Grant Program (1S10RR023401 and 1S10RR023043). Disclosure/conflict of interest: K.E.E. and A.B. have intellectual property rights at NordicNeuroLab AS. A.B. is a board member at NordicNeuroLab. K.S. is a co-founder of Imaging Biometrics LLC, a company that develops medical image processing software. She and her family have equity interest in, receive income from, and own intellectual property being developed. P.Y.W. is on Advisory Boards for Genentech and Novartis. T.B., Pharmaceutical consulting: 1) Merck & Co., Inc., 2) Roche, 3) Kirin Pharmaceuticals; CME lectures/material: 1) Up to Date, Inc., 2) Robert Michael Educational Institute LLC, 3) Educational Concepts Group, 4) Research to Practice, 5) Oakstone Medical, 6) Publishing, 7) American Society of Hematology; other consulting: 1) Champions, 2) Biotechnology, 3) Advance Medical; research support: 1) Pfizer, 2) Astra Zeneca, 3) Millennium. B.R. is on the consultant-advisory board of Siemens Medical.
- 2
This article refers to supplementary materials, which are designated by Tables S1 to S3 and Figures S1 and S2 and are available online at www.transonc.com.